Bezwoda W R, Derman D P, Perkins S, Cassel R
J Antimicrob Chemother. 1985 Feb;15(2):239-45. doi: 10.1093/jac/15.2.239.
Sixty neutropenic patients with infection were studied in a randomized trial comparing treatment with latamoxef (moxalactam) alone or with cephradine and tobramycin. The two treatment groups were comparable in respect to their clinical sites of infection, degree of neutropenia underlying malignancy, and organisms. Forty-two bacterial isolates were obtained from various clinically infected sites. All but two of these isolates were sensitive to latamoxef (30 highly sensitive, ten moderately sensitive). In contrast 29 of the isolates were resistant to cephradine and eight were resistant to both cephradine and tobramycin. Control of infection was achieved in 72% of patients treated with latamoxef and 55% treated with cephradine plus tobramycin. Latamoxef appears to be an effective antibiotic for the treatment of neutropenic patients with infection.
在一项随机试验中，对60例感染的中性粒细胞减少患者进行了研究，比较单独使用拉氧头孢（羟羧氧酰胺菌素）或联合头孢拉定和妥布霉素进行治疗的效果。两个治疗组在感染的临床部位、潜在恶性肿瘤的中性粒细胞减少程度以及病原体方面具有可比性。从各个临床感染部位分离出42株细菌。除两株外，所有这些分离株对拉氧头孢敏感（30株高度敏感，10株中度敏感）。相比之下，29株分离株对头孢拉定耐药，8株对头孢拉定和妥布霉素均耐药。接受拉氧头孢治疗的患者中72%的感染得到控制，接受头孢拉定加妥布霉素治疗的患者中这一比例为55%。拉氧头孢似乎是治疗感染的中性粒细胞减少患者的一种有效抗生素。
